| Closed |
SWOG-9313 |
Phase III Comparison of Adjuvant Chemotherapy with High-Dose Cyclophosphamide plus Doxorubicin (AC) versus Sequential Doxorubicin followed by Cyclophosphamide (A’C) in High-Risk Breast Cancer… |
3/15/1994 |
5/1/1997 |
98% |
|
Published
|
| Closed |
S0232 |
Phase III Double-Blinded Placebo Controlled Previously Untreated Multiple Myeloma |
11/1/2004 |
5/11/2007 |
40% |
|
Published
|
| Closed |
S0777 |
Phase III LD vs. VLD for Induction, followed by Transplant in Multiple Myeloma |
4/1/2008 |
2/1/2012 |
100% |
|
Published
|
| Closed |
S0521 |
Phase III Maint. vs. Obs. for Low and Intermediate Risk APL |
6/1/2007 |
|
19% |
|
Published
|
| Closed |
S1815 |
Phase III Randomized for advanced biliary tract cancers |
12/3/2018 |
2/15/2021 |
100% |
|
|
| Closed |
SWOG-9043 |
Phase III Randomized Trial of Beta Carotene vs. Placebo in Prevention of Second Primaries in Stages I and II Head and Neck Cancer |
9/1/1993 |
11/1/1994 |
5% |
|
|
| Closed |
S0106 |
Phase III Starndard + Mylotarg vs. Standard + Daunomycin/Ara-C for AML Under Age 61 |
5/15/2004 |
8/20/2009 |
93% |
|
Published
|
| Closed |
S1826 |
Phase III Study of AVD plus nivolumab or BV in pts >/= 12 years in newly diagnosed, advanced cHL |
7/19/2019 |
12/1/2022 |
100% |
|
|
| Closed |
SWOG-8833 |
Phase ll Investigation of Chlorambucil and Fludarabine Monophosphate in Relapsed or Refractory Chronic Lymphocytic Leukemia |
5/15/1989 |
4/15/1991 |
88% |
|
Published
|
| Closed |
SWOG-8734 |
Phase ll Trial of Low Dose PALA and High Dose 5-FU as a Short Term Infusion in the Treatment of Adeno-carcinoma of the Stomach |
3/1/1988 |
1/1/1990 |
86% |
|
Published
|
| Closed |
SWOG-8814 |
Phase lll Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive… |
5/15/1989 |
8/1/1995 |
100% |
|
Published
|
| Closed |
S1500 |
PhII: MET inhibitors for papillary RCC |
4/5/2016 |
|
100% |
|
|
| Open |
S1802 |
PhIII Rando SST v. SST+Surgery or Radiation for Met Prostate Cancer |
9/17/2018 |
|
68% |
|
|
| Closed |
S1008 |
Physical activity & dietary change weight loss in breast & colorectal survivors Ph II |
3/1/2012 |
7/1/2014 |
100% |
|
|
| Closed |
S1312 |
PI/II Inotuzumab + CVP for R/R CD22+ ALL |
4/1/2014 |
8/2/2019 |
100% |
|
|
| Open |
S1905 |
PI/II OBI-3424 for R/R T-ALL/T-LBL |
8/17/2020 |
|
28% |
|
|
| Closed |
S1318 |
PII Blinatumomab/POMP for Elderly Ph-Neg ALL |
1/12/2015 |
9/29/2021 |
98% |
|
|
| Closed |
S1211 |
PII Optimal Induction for HRMM |
10/12/2012 |
|
100% |
|
|
| Closed |
S1203 |
PIII 7+3 vs IA vs IA+vorinostat for AML |
12/15/2012 |
11/4/2015 |
96% |
|
|
| Open |
S1803 |
PIII Daratumumab + Lenalidomide Post-Auto SCT Maint for MM |
6/27/2019 |
|
100% |
|
|
